Profil
Sylvain Guénette is currently the Chief Financial Officer & Director at TALLC Corp., Inc. He was previously the Chief Financial Officer & Controller at Labopharm, Inc. in 2011.
Aktive Positionen von Sylvain Guénette
| Unternehmen | Position | Beginn |
|---|---|---|
TALLC Corp., Inc.
 TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada. | Finanzdirektor/CFO | - |
Ehemalige bekannte Positionen von Sylvain Guénette
| Unternehmen | Position | Ende |
|---|---|---|
Labopharm, Inc.
 Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Finanzdirektor/CFO | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Health Technology |
TALLC Corp., Inc.
TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada. | Health Technology |
